Dolutegravir alone maintains HIV suppression in those treated early
French study confirms that people with HIV born abroad are less likely to receive integrase inhibitors than those born in France
Same-day viral load test installed in Uganda, but people with HIV still received results months later
Breastfeeding and HIV in the US and Canada: no transmissions, no consistency
Once-daily dolutegravir sufficient when taking TB treatment
Can testing for drug-gene interactions improve treatment success in people with HIV?
People with weakened immune systems still at risk of treatment failure, even with newer ART regimens
Real-world data confirm the efficacy of dolutegravir-based dual therapy
Age and CD4 count have the greatest influence on life expectancy in the modern HIV treatment era
